David Geffen School of Medicine at UCLA-ko ikertzaileekin lankidetzan egindako argitalpenak (1)

2019

  1. Management of common adverse events related to first-line dacomitinib use in EGFR mutation-positive non-small-cell lung cancer: A pooled safety analysis

    Future Oncology, Vol. 15, Núm. 13, pp. 1481-1491